Curable. Inc. Stock

Equities

A086460

KR7086460003

Biotechnology & Medical Research

End-of-day quote Korea S.E. 18:00:00 2024-05-06 EDT 5-day change 1st Jan Change
5,680 KRW -0.35% Intraday chart for Curable. Inc. +8.40% -13.55%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Dynamic Chart
Curable. Inc. agreed to acquire 8.5% stake in Pharma Biotech Korea Co., Ltd from Pharma Biotech Korea for KRW 8.5 billion. CI
Curable. Inc. announced that it has received KRW 5.0009986 billion in funding from GW Vitek CO.,LTD. CI
SNP Genetics Inc. announced that it has received KRW 10 billion in funding from Kalis BNT Co., Ltd. CI
Curable. Inc. announced that it expects to receive KRW 9.999995 billion in funding from GW Vitek CO.,LTD. CI
SNP Genetics Inc. announced that it expects to receive KRW 10 billion in funding from Kalis BNT Co., Ltd. CI
An unknown buyer agreed to acquire 16.82% of stake in SNP Genetics Inc. from Jo, Jin-hwan and others for KRW 3.7 billion. CI
SNP Genetics Inc. announced that it has received KRW 2.49999872 billion in funding CI
SNP Genetics Inc. announced that it expects to receive KRW 2 billion in funding CI
SNP Genetics Inc. announced that it expects to receive KRW 2.49999872 billion in funding CI
GW Vitek CO.,LTD. agreed to acquire a 40.7% stake in SNP Genetics Inc. from Hyoung-doo Shin and Myung-cheol Kim for KRW 9.4 billion. CI
Tranche Update on SNP Genetics Inc.'s Equity Buyback Plan announced on November 2, 2020. CI
SNP Genetics Inc.'s Equity Buyback announced on November 2, 2020, has expired with 110,000 shares, for KRW 104.72 million. CI
SNP Genetics Inc. announces an Equity Buyback for 277,777 shares, for KRW 1,000 million. CI
SNP Genetics Inc. authorizes a Buyback Plan. CI
SNP Genetics Inc. cancelled the acquisition of an additional 0.99% stake in Enzychem Lifesciences Corporation from Capitalworks Investment Co.,Ltd. CI
More news
1 day-0.35%
1 week+8.40%
Current month-5.02%
1 month-11.11%
3 months-0.18%
6 months-10.55%
Current year-13.55%
More quotes
1 week
5 680.00
Extreme 5680
6 700.00
1 month
3 905.00
Extreme 3905
8 240.00
Current year
3 655.00
Extreme 3655
8 240.00
1 year
3 655.00
Extreme 3655
10 070.00
3 years
3 655.00
Extreme 3655
12 000.00
5 years
1 305.00
Extreme 1305
12 000.00
10 years
1 305.00
Extreme 1305
12 000.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 00-05-25
Chief Tech/Sci/R&D Officer 47 16-02-21
Director/Board Member 79 -
Members of the board TitleAgeSince
Chief Executive Officer 61 00-05-25
Director/Board Member 79 -
Chief Tech/Sci/R&D Officer 47 16-02-21
More insiders
Curable Inc, SNP Genetics Inc, is a Korea-based company mainly engaged in the analysis of genomes. The company is involved in the research and development of disease-related single nucleotide polymorphism (SNP) contents using SNP. These diseases include asthma, diabetes, osteoporosis, alcoholism, tuberculosis, cancer, multiple sclerosis, obesity, mental illness, metabolic disease, lupus disease. The Company is involved in the production and sale of Kobreed kits, as well as the provision of SNP Care. The Kobreed kits are medicine for discriminating Korean beef and imported meat. SNP Care is a gene analysis service. In addition, the Company is engaged in leasing of the places of business. The major customers include government agencies such as the Disease Control Headquarters and the Food and Drug Administration.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. A086460 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW